

This is a pre print version of the following article:

The Association Between Symptoms of Anxiety, Depression, and Cardiovascular Risk Factors: Results From an Italian Cross-Sectional Study / Rioli, Giulia; Tassi, Silvia; Mattei, Giorgio; Ferrari, Silvia; Galeazzi, Gian Maria; Mancini, Stefano; Alboni, Silvia; Roncucci, Luca. - In: JOURNAL OF NERVOUS AND MENTAL DISEASE. - ISSN 0022-3018. - 207:5(2019), pp. 340-347-347. [10.1097/NMD.0000000000000969]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

05/05/2024 13:37

Journal of Nervous and Mental Disease

Inflammation as a common factor in the occurrence of symptoms of anxiety, depression and cardiovascular risk factors: results from an Italian cross-sectional study.

--Manuscript Draft--

Manuscript Number:	JNMD-D-18-00085
Full Title:	Inflammation as a common factor in the occurrence of symptoms of anxiety, depression and cardiovascular risk factors: results from an Italian cross-sectional study.
Article Type:	Original Article
Keywords:	Anxiety; bio-psycho-social complexity; cardiovascular risk factors; depression; inflammation.
Corresponding Author:	Giulia Rioli, M.D. Universita degli Studi di Modena e Reggio Emilia Facolta di Medicina e Chirurgia Modena, MO ITALY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Universita degli Studi di Modena e Reggio Emilia Facolta di Medicina e Chirurgia
Corresponding Author's Secondary Institution:	
First Author:	Giulia Rioli, M.D.
First Author Secondary Information:	
Order of Authors:	Giulia Rioli, M.D.
	Silvia Tassi, M.D.
	Giorgio Mattei, M.D.
	Silvia Ferrari, M.D., Ph.D
	Gian Maria Galeazzi, M.D., Ph.D
	Stefano Mancini, M.D., Ph.D
	Silvia Alboni, Degree in Pharmacy and CTF, Ph.D
	Luca Roncucci, M.D., Ph.D
Order of Authors Secondary Information:	
Manuscript Region of Origin:	ITALY
Abstract:	<p>Cardiovascular Diseases and anxiety-depressive symptoms are among the most frequent clinical conditions in the Western World, often in comorbidity. Evidence about a shared pathophysiology suggests a mediating role by chronic systemic inflammation. Aims of this study were to measure the association between anxiety and depressive symptoms, cardiovascular risk factors and inflammatory markers. Outpatients aged ≥ 40 years undergoing colonoscopy after positive faecal occult blood test were enrolled; the following data were collected: BMI, blood pressure, glycaemia, lipid profile, CRP (C Reactive Protein), carotid thickness, scores at the Hospital Anxiety and Depression Scale (HADS), Temperament and Character Inventory (TCI), INTERMED-Self Assessment (IMSA) and SF-36. 54 patients were enrolled; 30.2% had anxiety symptoms, 18.9% depressive symptoms and 9.4% concomitant anxiety-depressive symptoms. Anxiety symptoms were associated with low HDL. Depressive symptoms were associated with CRP. Our results provide further support to evidence on the role of inflammation in the pathophysiology of depression.</p>
Suggested Reviewers:	Diogo Telles, MD, PhD Associate Professor, Universidade de Lisboa

	tellesdiogo@gmail.com Interested in the topic
	Matteo Balestrieri, MD, PhD Professor, Università degli Studi di Udine matteo.balestrieri@uniud.it Expert in the topic
	Ronald Burian, MD Senior Consultant, Evangelisches Krankenhaus „Königin Elisabeth Herzberge“, Berlin, university-affiliated hospital of the Charité (KEH), Berlin R.Burian@keh-berlin.de Interest in the topic
	Antonio Barbosa, MD, PhD Professor, University of Lisbon cbioetica@medicina.ulisboa.pt Interested in the topic



UNIMORE
UNIVERSITÀ DEGLI STUDI DI
MODENA E REGGIO EMILIA

Dipartimento di Medicina Diagnostica,
Clinica e di Sanità Pubblica

Sede
Via del Pozzo, 71 - 41124 - Modena, Italia

www.unimore.it
www.diclisn.unimore.it

March, 20th 2018

The Journal of Mental and Nervous Disease
Editorial Office

Dear Sir/Madame,

Please find enclosed a copy of a manuscript entitled "Inflammation as a common factor in the occurrence of symptoms of anxiety, depression and cardiovascular risk factors: results from an Italian cross-sectional study", which we submit for consideration for publication in *The Journal of Mental and Nervous Disease*.

We decided to submit our work to your Journal in view of its implications on the topic of the comorbidity between psychiatric symptoms of anxiety and depression and cardio-metabolic risk factors. Our results seem to provide a further confirmation of the so called "theory of inflammation" as the common pathophysiological ground of anxiety, depression and chronic medical conditions. Moreover, our study explores a relatively recent and, in our opinion, relevant field of research, that is, patients' self-perception of their physical and mental health, and its correlations to symptoms of anxiety and depression, providing new results which we think could be of interest to the Journal's readers.

The manuscript has not been submitted elsewhere. Abstracts concerning this work have been presented at the 25th European Congress of Psychiatry (Florence, 1-4 april 2017).

No conflict of interest has to be declared by any of the authors.

Authors of this article had access to all study data, are responsible for all contents of the article, and had authority over manuscript preparation and the decision to submit the manuscript for publication.

All listed authors have approved of the submission of the manuscript to your Journal.

If convenient, we can be contacted by e-mail at giulyrioli@hotmail.it.

Thank for considering our manuscript for publication, we look forward to your response in due course.

On behalf of the Authors,

Yours sincerely,

Giulia Rioli, M.D.

Running title:

Anxiety, depression and CVD risk.

Full Title:

Inflammation as a common factor in the occurrence of symptoms of anxiety, depression and cardiovascular risk factors: results from a cross-sectional study.

Article Type: Original Article

Authors: Giulia Rioli¹, Silvia Tassi¹, Giorgio Mattei^{1, 2, 3}, Silvia Ferrari^{1,4}, Gian Maria Galeazzi^{1,4}, Stefano Mancini⁵, Silvia Alboni⁶, Luca Roncucci⁵

¹Department of Diagnostics, Clinical and Public Health Medicine, Section of Psychiatry, University of Modena & Reggio Emilia, Modena, Italy.

²PhD School in Work, Development and Innovation, Department of Economics, University of Modena and Reggio Emilia & Marco Biagi Foundation, Modena, Italy

³Association for Research in Psychiatry, Castelnovo Rangone, Modena, Italy

⁴Center for Neuroscience and Neurotechnology, University of Modena & Reggio Emilia, Modena, Italy

⁵Department of Diagnostics, Clinic and Public Health Medicine, Section of Internal medicine, University of Modena & Reggio Emilia, Modena, Italy

⁶Department of Life Sciences, University of Modena & Reggio Emilia, Modena,

Italy.

Corresponding Author: Rioli Giulia, M.D., Clinica Psichiatrica, Policlinico di Modena, Via del Pozzo, 71 – 41124 Modena, tel. +39-059-4224305; fax +39-059-4224439; e-mail giulyrioli@hotmail.it

Corresponding Author's Institution: University of Modena and Reggio Emilia

Conflicts of interest: The authors have no competing interests to report.

ABSTRACT

Cardiovascular Diseases and anxiety-depressive symptoms are among the most frequent clinical conditions in the Western World, often in comorbidity. Evidence about a shared pathophysiology suggests a mediating role by chronic systemic inflammation. Aims of this study were to measure the association between anxiety and depressive symptoms, cardiovascular risk factors and inflammatory markers. Outpatients aged ≥ 40 years undergoing colonoscopy after positive faecal occult blood test were enrolled; the following data were collected: BMI, blood pressure, glycaemia, lipid profile, CRP (C Reactive Protein), carotid thickness, scores at the Hospital Anxiety and Depression Scale (HADS), Temperament and Character Inventory (TCI), INTERMED-Self Assessment (IMSA) and SF-36. 54 patients were enrolled; 30.2% had anxiety symptoms, 18.9% depressive symptoms and 9.4% concomitant anxiety-depressive symptoms. Anxiety symptoms were associated with low HDL. Depressive symptoms were associated with CRP. Our results provide further support to evidence on the role of inflammation in the pathophysiology of depression.

Keywords: anxiety; bio-psycho-social complexity; cardiovascular risk factors; depression; inflammation.

INTRODUCTION

Despite significant advances in diagnosis and treatment, Cardiovascular Diseases (CVDs) are among the leading causes of mortality and morbidity in the world (Roth et al., 2015). Also known as “silent killers”, they may be responsible for asymptomatic or pauci-symptomatic physiopathology until the onset of a full-blown cardiovascular event (Perk et al., 2012).

Therapy and prevention of CVDs is now increasingly feasible by means of: regular monitoring of established modifiable cardiovascular Risk Factors (RFs) (hypertension, smoking, dyslipidaemia, obesity/physical inactivity, diabetes mellitus); the study of emerging RFs (hyper lipoprotein(a), hyper homocysteinaemia, increased blood levels of C-Reactive Protein (CRP), and bacterial Lipopolysaccharides (LPS), metabolic syndrome (MS) (Wood, 2001; Grundy et al., 1999; Goff et al., 2014); non-invasive ultrasonographic measurements, such as FMD (Flow Mediated Dilatation) (Stain et al., 2008) and IMT (Intima-Media Thickness) (Polak et al., 2011), typically of the carotid artery. Up to 80% of prevention of CVDs may be achieved by effective improvements of lifestyle and monitoring of RFs (WHO, 2004).

Anxiety and depression too are highly prevalent clinical conditions, esteemed to become the second leading cause of disability worldwide by 2030 (WHO, 2017), with very high health care-related and social costs (Andrade et al., 2012).

Cardiovascular RFs and symptoms of anxiety and depression have a huge epidemiological impact, both independently considered and, even more, when comorbid (Suls & Bunde, 2005). Such strong evidence justifies the increasing amount of clinical research investigating the possible mechanisms underlying their association (Seldenrijk et al., 2010; Kollia et al., 2017).

Anxiety would act as an independent RF not only for CVDs, but also for the subclinical cardiovascular damage, measured either as carotid IMT (c-IMT), or AS (Arterial Stiffness), or ABI (Ankle-Brachial Index) (Roest et al., 2010). Anxiety seems to increase the risk of coronary heart disease (CHD) by 25% and cardiac mortality by almost 50%, compared to control group (Martens et al., 2010).

Similarly, major depression, depressive symptoms and history of major depression all significantly predict cardiac events (Frasure-Smith, 1995) and are associated with subclinical damage, i.e. IMT (Elovainio et al., 2005), especially in males, and with arterial calcification (Tiemeier et al., 2004).

For all these reasons, the inclusion of psycho-social evaluations in the multidimensional assessment of cardiovascular risk is now strongly recommended (Lichtman et al., 2008).

Stress-induced neurotransmitter and biochemical abnormalities accompanying anxiety and/or depression would sustain a subclinical chronic inflammatory state (Vogel, 1997). This contributes to dysregulation of the immunological system (Stein et al., 1985), of the autonomic nervous system, with increased sympathetic activity (Sajadieh et al., 2004), and of the hypothalamic-pituitary system (Akil et al., 1993). All these pathophysiological pathways are also known to be involved in CVD pathogenic factors such as chronic hyperglycemia, atherosclerosis and endothelial dysfunction.

Aim of the study

The primary aim of the study was to measure the association between anxiety and depressive symptoms and atherogenetic (FMD, c-IMT) and metabolic RFs for CVDs in a sample of subjects undergoing screening procedures.

The secondary aim was to measure the association of both anxiety and depressive symptoms and atherogenetic and metabolic RFs for CVDs with an inflammatory marker (CRP), to outline the role of inflammation as possible mediator of their relationship.

METHODS

Ethics

This research work is part of a wider project called "Overweight and inflammation of colorectal mucosa as intestinal marker of risk for cancer" that was approved by the Local Ethics Committee (EC 245/11-Prot.3885 / EC) and conducted according to the Declaration of Helsinki for ethical statement in medical research. Written informed consent was obtained by subjects accepting to be involved.

Study design and population

Cross-sectional design. The sample included 27 males and 27 females (n=54), recruited between March 2015 and July 2016 among patients referred to a screening colonoscopy. Patients were referred for colonoscopy by their GPs after occasional positive faecal occult blood or for suspicious intestinal complaints (abdominal pain, bowel movements abnormalities or haematochezia). Exclusion criteria were: being younger than 40 years; having a positive history for non-colorectal neoplasia, past or current, or systemic diseases in advanced stage, or an inflammatory bowel disease; not being able to fill in psychometric rating scales.

Clinical assessment and measurement methods

Data collection was conducted in three phases, before, during and after the colonoscopy.

Before the colonoscopy, patients were informed about the research project and asked for participation. Those providing consent were interviewed to enquiry about their smoking status, level of physical activity, alcohol consumption, medical history including ongoing medications. Biometric parameters were also measured and registered, including: weight (kg), height (cm), body mass index (BMI, kg/m²), waist and hips circumference (cm) and their ratio (waist-to-hip ratio, WHR), blood pressure (mmHg) and blood glucose (mg/dl), to establish the diagnosis of MS according to both the International Diabetes Federation (IDF) Consensus Worldwide definition of MS and the National Cholesterol Education Program - Adult Treatment Panel

(NCEP-ATP III) criteria (Grundy et al., 2005).

As part of the wider project, during colonoscopy, three micro-biopsies of ascending, descending and sigmoid colon were performed, stored and sent-off for analysis. A 10 ml-venous blood sampling was collected, with patients fasting for at least 8 hours, and analysed for CPR and lipid profile (total cholesterol, LDL, HDL, VLDL and triglycerides, mg/dl).

One week after undergoing colonoscopy, patients were invited to attend at a clinical meeting aimed at performing ultrasound measurement of left and right c-IMT and FMD. Psychometric assessment was also performed, offering assistance, if needed, to patients filling in the following four self-administered psychometric instruments:

1) The HADS (Hospital Anxiety and Depression Scale, Italian version) is a self-assessment rating scale made of 14 questions, 7 for anxiety and 7 for depression, developed to assess the presence and severity of depressive and anxious symptoms in the week before administration. Scores for each subscale range from 0 to 21, with scores categorized as follows: normal 0-7, mild 8-10, moderate 11-14, and severe 15-21. Although originally designed to be used with hospital populations, it has been found to perform well, with good psychometric properties, also among non-hospitalized subjects (Zigmond & Snaith, 1983; Bjelland et al., 2002; Terluin et al., 2009; Costantini et al., 1999).

2) The TCI (Temperament and Character Inventory, Italian version) is a self-assessment test designed by Cloninger and colleagues, whose list of true/false statements aims at identifying the intensity of and relationships between the basic personality dimensions of temperament (4 dimensions, Novelty Seeking (NS), Harm Avoidance (HA), Reward Dependence (RD) and Persistence (PS)) and character (3 dimensions, Self-Directedness (SD), Cooperativeness (CO) and Self-Transcendence (ST)); a 240-item validated Italian version was used (Cloninger, 1994; Fossati et al., 2007).

3) The SF-36 (Short Form-36, Italian version) is a well-known questionnaire assessing patients' perception of own general health and impact on quality of life. It consists of 8 scaled scores, pertaining to as many domains: vitality, physical

functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health (Ware et al., 1993; Apolone & Mosconi, 1998).

4) The INTERMED (INTERdisciplinary MEDicine) Self-Assessment (IMSA) is an instrument to assess bio-psycho-social case complexity in general health care by focusing on past, present and future health needs and risks of patients. Derived as a self-administered tool from the original version (a structured interview), it consists of 27 multiple-choice questions. The total score ranges from 0 to 60, reflecting the level of complexity and the related care needs/risks (van Reedt Dortland et al., 2017). Good psychometric and clinimetric properties were confirmed.

Statistical analysis

Statistical analysis was performed using the program STATA 13.1 (College Station, Texas).

Frequencies and percentages for dichotomous variables and mean, median, range and standard deviation for continuous variables were calculated as part of the descriptive analysis. Univariate and multivariate analyses were then performed as part of the inferential analysis, combining the latter with a parallel Stepwise Regression investigation, to control and enhance accuracy of data. Scores at HADS were selected as response variable (presence/absence of anxiety symptoms, of depressive symptoms and of both anxiety and depressive symptoms – cut-off of 8). For both regression models, the usual $p < 0.05$ threshold for statistical significance was used, but only variables reaching a significance level < 0.25 at the univariate analysis were included in the multiple analysis, to limit type II errors.

RESULTS

Descriptive statistical analysis

A total of 54 patients (27 males, 50%) were enrolled. Sample characteristics and measures are described in tables I (continuous variables) and II (dichotomic variables).

Anxiety symptoms had a higher prevalence than depressive ones (n=16, 30.2% vs. n=10, 18.9%, respectively). Only 5 patients (9.4% of the sample) simultaneously showed both anxiety and depressive symptoms.

- *Display table I and II about there* -

Univariate inferential statistical analysis

Anxiety symptoms were found to be significantly associated to HDL (OR=0.08; p=0.02), right c-IMT (OR=2.64; p=0.03), the Mental Component Summary (MCS) item of SF-36 (OR=10.5; p=0.01). Depressive symptoms were found to be significantly associated to CRP (OR=6.75; p=0.03) and to MCS SF-36 (OR=13.33; p=0.00). Anxiety and depressive symptoms were found to be significantly associated to MCS SF-36 scale (OR=12.9; p=0.01).

Multivariate inferential statistical analysis

In the multivariate regression analysis, anxiety symptoms were found to be significantly associated to low HDL values (OR=0.30; p=0.01), as shown in table III. Depressive symptoms were confirmed to be significantly associated to MCS SF-36 (OR=26.44; p=0.01) and CRP (OR=13.15; p=0.03), while finally the combined presence of anxious-depressive symptoms was found to be associated only to MCS SF-36 (OR=11.16; p=0.02).

- *Display table III about there* -

DISCUSSION

The aim of the present research was to measure the association of a range of potential cardio-metabolic RFs, including inflammation, to the presence of symptoms of anxiety and depression in a sub-clinical sample of subjects undergoing colonoscopy as a screening procedure.

More than half of subjects in our sample (64.8%) were found to have a higher BMI than normal, with a frequency of overweight almost double (40.7%) compared to frank obesity (20.4%), according to Italian 2012 ISTAT data. The prevalence of MS was 42.6%, slightly higher than the 20 to 40% rate usually reported in the US and Europe (Ford et al., 2002). This may be related to the age range of the sample and/or to the worse level of glycaemic control, considering that the prevalence of MS is positively related to older age and higher levels of blood sugar. Hypertriglyceridemia was another common feature in our sample (Trenti et al., 2009). Almost two thirds of the sample were affected by hypertension, a result consistent to similar recent Italian epidemiological evidence. The prevalence of diabetes mellitus type II (2 subjects) was in line with Italian epidemiological data (Gnavi et al., 2018); moreover, 12 subjects had poor glycaemic control fulfilling criteria for “pre-diabetes”: this is known to be a positive predictor for the development of diabetes within 5-10 years (Dall et al., 2014).

One third of the sample reported being a smoker, a high prevalence when compared to Italian 2012 population data of 2012 (Tondi, 2011; Pacifici, 2013), and more typical of a younger population than that here described. Smoking status could be coherent with the overall high prevalence of anxious/depressive symptoms, considering the frequent association observed between smoking and emotional distress (Weinberger et al., 2010).

In the sample, 63% of patients described themselves as leading a sedentary lifestyle, a higher prevalence than the one described by ISTAT 2009 survey of the Italian population (ISTAT, 2016). This may be related to the older age of our sample, but also to the over-simplicity of the yes-or-no format of the question, not allowing

respondents to provide further specification.

Psychiatric symptoms of anxiety and/or depression were highly prevalent. While bearing in mind that the HADS is designed as a screening tool and not as diagnostic instrument, the fact that half of a population of out-patients, in a non-psychiatric setting, was found positive for at least mild anxiety and/or depression is nevertheless worth of attention. Even more considering that these symptoms were presumably unrecognized and/or untreated: of the 26 patients affected, only 6 were receiving treatment, suggesting a therapeutic gap consistent with other findings (Corrigan et al., 2014; Mattei et al., in press). This is known to have many potential bio-psycho-social negative consequences (social isolation, decline in work performance, increase in use/abuse of medications, alcohol or drugs, increased hospitalization, self-harm behaviours, worse prognosis of medical conditions) (Wang et al., 2007).

Symptoms of anxiety were associated with subclinical cardiovascular risk (right c-IMT), and the association showed a trend towards statistical significance also for subjects with concomitant anxiety and depressive symptoms ($p=0.06$). These findings provide further support to the clinical relevance of including assessment of anxiety and depression on a regular basis in medical settings (Santos et al., 2015). Our findings may also contribute further evidence supporting the “theory of inflammation” as the common pathophysiological ground of anxiety, depression and chronic medical conditions including CVDs: symptoms of depression were found to correlate to CRP (Collino et al., 2006).

Moreover, reduced HDL values was found to be a protective factor for anxiety both at the univariate and at the multivariate analysis ($OR=0.08$ and 0.30 respectively); this finding would fit well a psychogenic theory of obesity, corroborating the role of "comfortable food" as affective compensation, with antidepressant/anti-anxiety effect (Burbatti & Castoldi, 1999).

Finally, increasing levels of anxiety and/or depression were found to correlate to the MCS score of SF-36, consistently with previous evidence reported in various clinical populations (Buendia et al., 2011). This is a highly expectable finding supporting the

evidence that depression and emotional distress have a major impact on quality of life, even more than other chronic conditions (Murray, 1998).

The following limitations in the present research have to be acknowledged. Firstly, the cross-sectional design does not allow causal inferences of the relationship between the psychiatric symptomatology and the cardiovascular changes. Yet, the adoption of such design made the study feasible, and is consistent with the majority of studies currently published in this field. Secondly, the limited sample size and the selected population may affect the generalizability of results. Nonetheless, these results were found to be consistent with evidence provided by international literature. Thirdly, cases were selected not in the general population but among subjects undergoing an anti-cancer screening procedure (colonoscopy) and already presented signs or symptoms. Despite this may limit inference, it provides a “real-world” perspective on patients, reproducing the intertwining of risk factors and causal pathways between different clinical conditions (CVDs, cancer, anxiety and depressive mild-to-moderate conditions). Finally, data were not complete for some of the variables (e.g. TCI dimensions). Yet, the significance level of such variables at the univariate analysis excluded anyway the possibility of including them in the multiple analysis, suggesting that this limitation did not affect the final results. In spite of such limitations, the integration of clinical and instrumental (ultrasound) data in an integrated psycho-neuro-endocrine-immunological perspective is an original approach in psychiatric research and could represent a strength of the study.

CONCLUSIONS

The present research contributes to supporting the need for early detection and management of anxiety and depressive symptoms in a population under study for prevention of cancer and CVDs and provides further elements on the pathophysiological key role of inflammation. Symptoms of anxiety and of comorbid anxiety and depression were associated to subclinical cardiovascular RFs. Emotional symptoms were also found to correlate to inflammatory markers and metabolic RFs.

The exploration of the dimension of self-perceived quality of life and subjective, psychic symptomatology could improve cardiovascular risk assessment, as also Engel's bio-psycho-social model originally suggested (Engel, 1980). Further studies specifically focused on the investigation of inflammatory parameters are needed in order to understand more comprehensively the complex role of chronic inflammation in the association between psychiatric symptoms and CVDs.

REFERENCES

Akil H, Haskett RF, Young EA, Grunhaus L, Kotun J, Weinberg V, Greden J, Watson SJ (1993). Multiple HPA profile in endogenous depression: effect of age and sex on cortisol and β -endorphin. *Biol Psychiatry* 33:73-85.

Andrade LH, Wang YP, Andreoni S, Silveira CM, Alexandrino-Silva C, Siu ER, Nishimura R, Anthony JC, Gattaz WF, Kessler RC, Viana MC (2012). Mental disorders in megacities: findings from the Sao Paulo megacity mental health survey, Brazil. *PLoS One* 7(2):e31879.

Apolone G & Mosconi P (1998). The Italian SF-36 Health Survey. Translation, Validation and Norming. *J of Clinical Epidemiology* 51(11):1025-1036.

Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002). The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res* 52(2):69-77.

Buendia F, Almenar L, Martinez-Dolz L, Sanchez-Lazaro I, Navarro J, Agüero J (2011). Relationship between functional capacity and quality of life in heart transplant patients. *Transplantation Proceedings* 43(6),2251-2252.

Burbatti G & Castoldi I (1999). In guerra col cibo. Feltrinelli.

Cloninger CR (1994). The temperament and character inventory (TCI): A guide to its development and use. Center for Psychobiology of Personality, Washington University, St Louis (MO).

Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiernemann C, Fantozzi R (2006). Modulation of the oxidative stress and inflammatory response by PPAR-

gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. *Eur J Pharmacol* 530 (1-2):70-80.

Corrigan PW, Druss BG, Perlick DA (2014). The impact of Mental Illness Stigma on seeking and participating in Mental Health Care. *Psychological Science in the Public Interest* 15(2):37-70.

Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G (1999). Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. [Supportive Care in Cancer](#) 7(3):121-127.

Dall TM, Yang W, Halder P, Pang B, Massoudi M, Wintfeld N, Semilla AP, Franz J, Hogan PF (2014). The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. *Diabetes Care* 37 (12): 3172-9.

Elovainio M, Keltikangas-Järvinen L, Kivimäki M, Pulkki L, Puttonen S, Heponiemi T, Juonala M, Vikari JS, Raitakari OT (2005). Depressive symptoms and carotid artery intima-media thickness in young adults: the Cardiovascular Risk in Young Finns Study. *Psychosom Med* 67 (4):561–7.

Engel GL (1980). The Clinical Application of the Biopsychosocial model. *American J Psychiatry* 137:5.

Ford ES, Giles WH, Dietz WH (2002). Prevalence of the metabolic syndrome among US adults: findings from the third. National Health and Nutrition Examination Survey. *JAMA* 287:356-359.

Fossati A, Cloninger CR, Villa D, Borroni S, Grazioli F, Giarolli L, Battaglia M, Maffei C (2007). Reliability and validity of the Italian version of the Temperament and Character Inventory-Revised in an outpatient sample. *Comprehensive Psychiatry* 48(4):380–387.

Frasure-Smith N (1995). The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? *Health Psychol* 14(5):388-98.

Gnavi R, Migliardi A, Maggini M, Costa G (2018). Prevalence of and secular trends in diagnosed diabetes in Italy (2018). *Nutrition, Metabolism and Cardiovascular diseases* 28;3: 219-225.

Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lack-

land DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2013). ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 129: S49-S73.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 112(17):2735-52.

Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V (1999) Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation* 100(13): 1481-92.

International Diabetes Federation, IDF (2006). The International Diabetes Federation (IDF) Worldwide Definition of the Metabolic Syndrome. IDF Communications, Brussels. Available at: <https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome>

ISS, Istituto Superiore di Sanità (2012). Il progetto cuore. Epidemiologia a prevenzione delle malattie cerebro e cardiovascolari. Available at: <http://www.cuore.iss.it/fattori/CuoreData.asp>

ISTAT (2016). Indagine statistica multiscopo sulle famiglie. Aspetti della vita quotidiana. Available at: http://dati.istat.it/Index.aspx?DataSetCode=DCCV_AVQ_PERSONE&Lang=

ISTAT (2016). Diabete: dati di prevalenza a livello nazionale. Available at: <http://www.epicentro.iss.it/igea/diabete/prevalenza.asp#istat>

Kollia N, Panagiotakos D, Georgousopoulou E, Chrysoshoou C, Yannakoulia M, Stefanadis C, Chatterji S, Haro JM, Papageorgiou C, Pitsavos C, for the ATTICA Study investigators (2017). Explor-

ing the path between depression, anxiety and 10-year cardiovascular disease incidence, among apparently healthy Greek middle-aged adults: The ATTICA study. *Maturitas* 106:73-79.

Lichtman JH, Bigger T, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, Mark DB, Sheps DS, Taylor CB, Froelicher ES; American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association (2008). Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. *Circulation* 118(17):1768-75.

Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA (2010). Scared to Death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease: The Heart and Soul Study. *Arch Gen Psychiatry* 67(7):750-758.

Mattei G, Padula MS, Rioli G, Arginelli L, Bursi R, Bursi S, Epifani AM, Pingani L, Rigatelli M, Rosato FM, Sacchetti A, Galeazzi GM, Ferrari S (in press). Metabolic syndrome, anxiety and depression in a sample of Italian primary care patients. *Journal of Nervous and Mental Disease*, in press.

Murray CJL (1998). *The Global Burden of Disease: a comprehensive assessment of mortality and disability from disease. Injuries and Risk Factors in 1990 and projected to 2020*, Boston: Mass, Harvard University Press (30).

Pacifici R (2013) *Rapporto sul fumo in Italia 2012*. XV Congress on Smoking and National Health Service, Rome.

Perk J, De Backer G, Gohlke I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syv  nne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG) (2012). *European Guidelines on cardiovascular disease preven-*

tion in clinical practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J* 33(13):1635-701.

Polak FJ, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB (2011). Carotid-Wall Intima-Media Thickness and Cardiovascular Events. *New Engl J Med* 365:213-21.

Roest AM, Martens EJ, de Jonge P, Denollet J (2010). Anxiety and risk of incident coronary heart disease. *J Am Coll Cardiol* 56(1):38-46.

Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA, Murray CJL (2015). Demographic and epidemiologic drivers of global cardiovascular mortality. *The New England Journal of Medicine* 372:1333-1341.

Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF (2004). Increased heart rate and reduced heart rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent disease. *Eur Heart J* 25:363-370.

Santos IS, Goulart AC, Brunoni AR, Kemp AH, Lotufo PA, Bensenor IM (2015). Anxiety and depressive symptoms are associated with higher carotid intima-media thickness. Cross-sectional analysis from ELSA-Brasil baseline data. *Atherosclerosis* 240:529-534.

Seldenrijk A, Vogelzangs N, van Hout HP, van Marwijk HW, Diamant M, Penninx BW (2010). Depressive and anxiety disorders and risk of subclinical atherosclerosis, findings from the Netherlands Study of Depression and Anxiety (NESDA). *Journal of Psychosomatic Research* 69: 203-210.

Stain JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mothler ER, Najjar SS, Rembold CM, Post WS; American Society of Echocardiography Carotid Intima-Media Thickness Task Force (2008). Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. *J Am Soc Echocardiogr* 21(2):93-111.

Stein M, Keller SE, Schleifer SJ (1985), Stress and immunomodulation: the role of depression and neuroendocrine function, *Journal of Immunology* 135(Suppl 2):827s-833s.

Suls J & Bunge J (2005). Anger, anxiety, and depression as risk factors for cardiovascular disease: the problems and implications of overlapping affective dispositions. *Psychol Bull* 131(2):260-300.

Terluin B, Brouwer E, van Marwijk H, Verhaak P, van der Hoorst H (2009). Detecting depressive and anxiety disorders in distressed patients in primary care; comparative diagnostic accuracy of the Four- Dimensional Symptom Questionnaire (4DSQ) and the Hospital Anxiety and Depression Scale (HADS). *BMC Family Practice*;10:58.

Tiemeier H, van Dijck W, Hofman A, Witteman JC, Stijnen T, Breteler MM (2004). Relationship between atherosclerosis and late-life depression: Rotterdam study. *Arch Gen Psychiatry* 61:369–76.

Tondi L (2011). Il «Progetto Diabete» della provincia di Modena: risultati del progetto di gestione integrata. *Dialogo sui farmaci* 2:57-61.

Trenti C, Negri EA, Iori I, Favali D (2009). Hypertriglyceridemia, a common dyslipidemia of complex definition. *Italian Journal of Medicine* 3,220-226.

Van Reedt Dortland A, Peters L, Boenink AD, Smit JH, Slaets JPJ, Hoogendoorn AW, Joos A, Latour CHM, Stiefel F, Burrus C, Guitteny-Collas M, Ferrari S (2017). Assessment of Biopsychosocial Complexity and Health Care Needs: Measurement Properties of the INTERMED Self-Assessment Version. *Psychosomatic Medicine* 79(4):485-492.

Vogel RA (1997). Coronary risk factors, endothelial function, and atherosclerosis: a review. *Clin Cardiol* 20(5):426-32.

Wang PS, Angermeyer M, Borges G, Bruffaerts R, Chiu WT, de Girolamo G, Fayyad J, Gureje O, Haro JM, Huang Y, Kessler RC, Kovess V, Levinson D, Nakane Y, Oakley Brown MA, Ormel JH, Posada-Villa J, Aguilar-Gaxiola S, Alonso J, Lee S, Heeringa S, Pennell BE, Chatterji S, Ustün TB (2007). Delay and failure in treatment seeking after first onset of mental disorders in the World Health Organization's World Mental Health survey initiative. *World psychiatry* 6(3):177–185.

Ware JE, Snow KK, Kosinski M, Gandek B (1993). SF-36 Health Survey: Manual and interpretation guide. Boston, MA: The Health Institute.

Weinberger AH, Desai RA, McKee SA (2010). Nicotine withdrawal in U.S. smokers with current mood, anxiety, alcohol use, and substance use disorders. *Drug Alcohol Depend* 108(1-2);7-12.

WHO (2017). "Depression: let's talk" says WHO, as depression tops list of causes of ill health. Available at: <http://www.who.int/mediacentre/news/releases/2017/world-health-day/en/>

WHO (2004). The Global Burden of Disease: 2004 update. Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part4.pdf

Wood D, Joint European Societies Task Force (2001). Established and emerging cardiovascular risk factors. *Am Heart J* 141(2 Suppl):S49-57.

Zigmond AS & Snaith RP (1983). The Hospital Anxiety and Depression Scale, *Acta Psychiatr Scand* 67(6):361-70.

Table I - Descriptive statistical analysis. Demographic and clinical characteristics of the sample (continuous variables).

Variable	N	Mean	SD	Range
Age (years)	54	61.3	9.2	44-82
Weight (Kg)	54	76.2	15.9	49-113
Height (cm)	54	1.7	0.1	150-191
BMI	54	27	4.1	18.8-38.1
Waist Circumference	54	99.9	14.6	65-129
Hip Circumference	54	102.7	9.5	81-120
Total Cholesterol (mg/dl)	54	194.8	18.2	156-241
Triglycerides (mg/dl)	54	134	44.7	57-220
VLDL Cholesterol (mg/dl)	54	26.8	9	11-44
PA Systolic (mmHg)	49	146.1	18.2	110-180
PA Diastolic (mmHg)	49	82.4	10.1	60-100
Glycaemia (mg/dl)	54	95.41	18.6	64-194
CRP (mg/dl)	54	0.6	0.45	0.2-2.1
IL 1 beta	18	6	9.3	.8 - 41.7
IMT Right	51	812.3	274	486-1500
IMT Left	51	856.6	313.5	503-2000
FMD 1 st minute	50	9.4	5.8	0 - 21.1
FMD 3 rd minute	50	8.3	6.1	-7.2 - 20
FMD 1 st -3 rd minute	50	-1.4	6.4	-22.5-15.5
Psychiatric symptoms (HADS)				
HADS – Anxiety	44	5.9	4.1	0 - 15

HADS – Depression	44	4.6	3.2	0 - 11
Temperament and Character Dimensions (TCI)				
Novelty Seeking	37	22.3	3.7	15- 29
Avoidance	37	18.6	3.1	10-24
Reward Dependence	37	10.9	2.6	6-16
Persistency	37	5.4	1.1	3-8
Self-Directedness	37	26.1	4.1	18-34
Cooperativeness	37	21.6	4.6	12-31
Self-Transcendence	37	20.4	3.3	12-26
INTERMED Self-Assessment (IMSA)				
IMSA total score	40	7.6	3.9	0-18
IMSA Biologic domain	40	3.2	2.4	0-9
IMSA Psychologic domain	40	1.9	1.8	0-7
IMSA Social domain	40	1.1	1.1	0-5
IMSA Health Services domain	40	1.5	1.6	0-6
IMSA History	40	5.2	2.8	0-12
IMSA Present	40	2.8	2.9	0-13
IMSA Future	40	7.6	3.8	0-18
Quality of life (SF-36)				
Physical Functioning SF-36	45	80.4	20.6	25-100
Role limitation because of physical health problems SF-36	45	75.6	33.1	0-100
Bodily pain SF-36	45	70	26.1	0-100

General Health perception SF-36	45	65.4	15.2	30-92
Social Functioning SF-36	45	79.4	18.9	12.5-100
Role limitations because of emotional problems SF-36	45	83.7	29	0-100
General Mental Health SF-36	45	74.8	15.1	32-100
Mental Component Summary (MCS) SF-36	45	51.7	9.1	22.8- 66.1
Physical Component Summary (PCS) SF-36	45	47.1	8.6	26.1-58.8

List of Abbreviations: BMI=Body Mass Index, VLDL=Very Low Density Lipoproteins, PA=Arterial Pressure, CRP=C Reactive Protein, IL1=Interleukine 1, IMT=Intima-Media thickness, FMD=Flow mediated dilatation, HADS-A=Hospital Anxiety and Depressive scale - anxiety subscale, HADS-D=Hospital Anxiety and Depressive scale - depression subscale, SF-36=Short Form 36 Items, IMSA, INTERMED=The INTERMED (INTERdisciplinary MEDicine) Self-Assessment.

Table II - Descriptive statistical analysis. Demographic and clinical characteristics of the sample (dichotomous variables).

Dichotomous variables	N	%
Age		
<62 years	27	50
≥62 years	27	50
Sex		
Females	27	50
Males	27	50
BMI		
<25 kg/m ²	19	35.2
≥25 kg/m ²	22	40.7
≥30 kg/m ²	11	20.4
≥35 kg/m ²	2	3.7
MS ATP III		
No	33	61.1
Yes	21	38.9
MS IDF		
No	32	59.3
Yes	22	40.7
Total cholesterol		
<200 mg/dl	34	63
≥200 mg/dl	20	37
LDL		
<130 mg/dl	39	72.2
≥130 mg/dl	15	27.9
Triglycerides		
<150 mg/dl	34	63

≥150 mg/dl	20	37
HDL		
M≥40 mg/dl; F≥50 mg/dl	35	64.8
M<40 mg/dl; F<50 mg/dl	19	35.2
Hypertension		
<140/90 mmHg	21	38.9
≥140/90 mmHg	33	61.1
Diabetes		
<126 mg/dl	52	96.3
≥126 mg/dl	2	3.7
Hyperglycaemia		
≥100 mg/dl	14	25.9
<100 mg/dl	40	71.1
MAI/cardiopathy		
No	53	98.2
Yes	1	1.9
CRP		
<0.08 mg/dl	30	55.6
≥0.08 mg/dl	24	44.4
Smoke		
No	36	66.7
Yes	18	33.3
Alcohol		
No	17	31.5
Yes	37	68.5
Sedentary		
No	20	37
Yes	34	63
Anxiolytics		
No	50	92.6

Yes	4	7.4
Antidepressants		
No	52	96.3
Yes	2	3.7
Right Intima-Media Thickness		
<900 um	39	73.6
≥900 um	8	15.1
≥1500 um	6	11.3
Left Intima-Media Thickness		
<900 um	40	75.5
≥900 um	9	17
≥1500 um	4	7.6
HADS-A		
<8	37	69.8
≥8	16	30.2
HADS-D		
<8	43	81.1
≥8	10	18.9
HADS A and D		
A or D <8	48	90.6
A or D ≥8	5	9.4
Vitality SF-36		
>40	52	98.1
≤40	1	1.9
MCS SF-36		
>42	45	84.9
≤42	8	15.1
IMSA		
≤21	51	100
>21	0	0

FMD 1st minute		
≥ 9.70%	26	51
<9.70%	25	49
FMD 3rd minute		
≥7.75%	28	54.9
<7.75%	23	45.1
FMD Delta 1st -3rd minute		
≥-0.87%	24	47.1
<-0,87%	27	52.9

List of abbreviations: BMI=Body Mass Index, MS=Metabolic Syndrome, ATP III=Adult Treatment Panel III report, IDF=International Diabetes Federation, LDL=Low Density Lipoproteins, HDL=High density Lipoproteins, MAI=Acute Myocardial Infarction, CRP=C Reactive Protein, HADS-A=Hospital Anxiety and Depressive scale - anxiety subscale, HADS-D=Hospital Anxiety and Depressive scale - depression subscale, SF-36=Short Form 36 Items, IMSA=The INTERMED (INTERdisciplinary MEDicine) Self-Assessment, FMD=Flow Mediated Dilatation.

Table III – Univariate and multivariate inferential statistical analysis for anxiety and/or depressive symptoms.

UNIVARIATE INFERENTIAL STATISTICAL ANALYSIS			
<i>HADS-A</i>	OR	p-value	95% CI
Low HDL	0.08	0.02	0.01-0.7
Right intima-media thickness	2.64	0.03	1.1-6.3
MCS SF-36	10.5	0.01	1.8-60.3
<i>HADS-D</i>	OR	p-value	95% CI
CRP	6.75	0.03	1.3-35.8
MCS SF-36	13.33	0.00	2.4-73.5
<i>HADS-A and D</i>	OR	p-value	95% CI
MCS SF-36	12.9	0.01	1.7-96.8
MULTIVARIATE INFERENTIAL STATISTICAL ANALYSIS			
<i>HADS-A</i>	OR	p-value	95% CI
Low HDL	0.30	0.01	0.00-0.4
<i>HADS-D</i>	OR	p-value	95% CI
MCS SF-36	26.44	0.01	2.5-274.2
CRP	13.15	0.03	1.3-128.4
<i>HADS-A and D</i>	OR	p-value	95% CI
MCS SF-36	11.16	0.02	1.4-89.03

List of abbreviations: HADS=Hospital Anxiety and Depressive scale, HDL=High density Lipoproteins, MCSF SF-36=Mental Component Summary Short Form-36 items, CRP=C Reactive Protein, OR=Odds Ratio, CI=Confidence Interval.



[Click here to access/download](#)

Copyright Transfer and Disclosure Form
copyrightTransfer 190318.pdf

